Roche: conditional approval for Gavreto in Europe

(CercleFinance.com) - Roche announces that the European Commission has granted conditional marketing authorisation for Gavreto as a single agent for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer (NSCLC).


This approval is based on results from the ongoing ARROW Phase I/II study, in which Gavreto led to durable responses in people with RET fusion-positive advanced NSCLC, Roche said.

Blueprint Medicines and Roche subsidiary Genentech market Gavreto in the US and Roche has exclusive marketing rights outside the US and in Asia, including China.


Copyright (c) 2021 CercleFinance.com. All rights reserved.